HealthPolitics

Pennsylvania Adds Anxiety, Tourette’s to Qualifying Conditions

Published on July 11, 2019 · Last updated July 28, 2020
pennsylvania adds anxiety as qualifying condition - header image
(benedek/iStock)

The Pennsylvania Health Department is adding anxiety disorders and Tourette’s syndrome to the list of conditions that can qualify people to obtain legal medical cannabis.

CBD, has proven particularly promising as an anti-anxiety treatment.

The heath secretary, Dr. Rachel Levine, announced Thursday she’ll be adding them as of July 20. They’ll join 21 other qualifying conditions recognized by the state, including cancer, epilepsy, post-traumatic stress disorder (PTSD), chronic pain, and, in some cases, opioid use disorder.

“I do not take this decision lightly, and do have recommendations for physicians, dispensary pharmacists and patients in terms of the use of medical marijuana to treat these conditions,” Levine said in a statement about the expansion. “For both conditions, medical marijuana is not first line treatment and should not replace traditional therapies but should be used in conjunction with them, when recommended by a physician.”

Related
Why More College Students Are Calming Anxiety With Medical Cannabis

Levine says her decision was based on the recommendation of the state’s Medical Marijuana Advisory Board and her own review of medical research literature.

Cannabidiol, or CBD, has proven particularly promising as an anti-anxiety treatment. Brazilian researchers in a small study found that patients with generalized social anxiety reported a significant decrease in anxiety after taking CBD, and brain scans showed cerebral blood-flow patterns consistent with an anti-anxiety effect. In another study, researchers found that patients suffering from social anxiety disorder reported less anxiety after taking CBD—reports backed up by objective indicators such as heart rate and blood pressure.

Nearly 111,000 Pennsylvanians have been certified for participation in the state’s medical marijuana program.

The Associated Press contributed to this report.

Shop highly rated dispensaries near you

Showing you dispensaries near
See all dispensaries
Leafly Staff
Leafly Staff
Leafly is the world’s largest cannabis information resource, empowering people in legal cannabis markets to learn about the right products for their lifestyle and wellness needs. Our team of cannabis professionals collectively share years of experience in all corners of the market, from growing and retail, to science and medicine, to data and technology.
View Leafly Staff's articles
Get good reads, local deals, and strain spotlights delivered right to your inbox.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.



Stay In Touch

Receive updates on new products, special offers, and industry news.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.

Leafly mobile app
Get high for less.
Download the Leafly app.
Download Leafly: Marijuana Reviews on the App Store
Download Leafly Marijuana Reviews on Google Play




* Statements made on this website have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Information provided by this website or this company is not a substitute for individual medical advice.


© 2024 Leafly, LLC
Leafly and the Leafly logo are registered trademarks of Leafly, LLC. All Rights Reserved.